PT  - JOURNAL ARTICLE
AU  - SHIGEO KOIDO
AU  - YUTAKA ENOMOTO
AU  - VASSO APOSTOLOPOULOS
AU  - JIANLIN GONG
TI  - Tumor Regression by CD4 T-Cells Primed with Dendritic/Tumor Fusion Cell Vaccines
DP  - 2014 Aug 01
TA  - Anticancer Research
PG  - 3917--3924
VI  - 34
IP  - 8
4099  - http://ar.iiarjournals.org/content/34/8/3917.short
4100  - http://ar.iiarjournals.org/content/34/8/3917.full
SO  - Anticancer Res2014 Aug 01; 34
AB  - Background/Aim: Vaccination with fusions of dendritic cells (DCs) and mucin-1 (MUC1)-positive tumor cells (FC/MUC1) induces MUC1-specific antitumor immunity. However, little is known about the function of Cluster of Differentiation (CD)4 T-cells primed with FC/MUC1 in MUC1 transgenic (MUC1.Tg) mice. Materials and Methods: CD4 T-cells primed with FC/MUC1 were analyzed by flow cytometry. Antitumor immunity by adoptive transfer of primed CD4 T-cells in Rag2−/− mice was assessed. Results: The effector and memory T-cells generated with FC/MUC1 were crucial to maintenance of long-term antitumor immunity. MUC1-8-mer peptide SAPDTRPA presented by FC/MUC1 was recognized by CD4 and CD8 T-cells. A subset of primed CD4 T-cells possessed cytotoxicity to lyse major histocompatibility complex (MHC) class I and MUC1 positive tumor cells. Interestingly, adoptive transfer of primed CD4 T-cells prevented lung metastasis in Rag2−/− mice. Conclusion: CD4 T-cells primed by FC/MUC1 play direct role in antitumor immunity.